Journal Article

DKFZ-2018-01145

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.

Deng, M. Y. (First author)DKFZ* ; Sill, M.DKFZ* ; Chiang, J. ; Schittenhelm, J. ; Ebinger, M. ; Schuhmann, M. U. ; Monoranu, C.-M. ; Milde, T.DKFZ* ; Wittmann, A.DKFZ* ; Hartmann, C. ; Sommer, C. ; Paulus, W. ; Gärtner, J. ; Brück, W. ; Rüdiger, T. ; Leipold, A. ; Jaunmuktane, Z. ; Brandner, S. ; Giangaspero, F. ; Nozza, P. ; Mora, J. ; Morales la Madrid, A. ; Cruz Martinez, O. ; Hansford, J. R. ; Pietsch, T. ; Tietze, A. ; Hernáiz-Driever, P. ; Stoler, I. ; Capper, D. ; Korshunov, A.DKFZ* ; Ellison, D. W. ; von Deimling, A.DKFZ* ; Pfister, S.DKFZ* ; Sahm, F.DKFZ* ; Jones, D. (Last author)DKFZ*

2018
Springer Berlin

This record in other databases:  

Please use a persistent id in citations: doi:10.1007/s00401-018-1865-4

Abstract: Diffuse leptomeningeal glioneuronal tumors (DLGNT) represent rare CNS neoplasms which have been included in the 2016 update of the WHO classification. The wide spectrum of histopathological and radiological features can make this enigmatic tumor entity difficult to diagnose. In recent years, large-scale genomic and epigenomic analyses have afforded insight into key genetic alterations occurring in multiple types of brain tumors and provide unbiased, complementary tools to improve diagnostic accuracy. Through genome-wide DNA methylation screening of > 25,000 tumors, we discovered a molecularly distinct class comprising 30 tumors, mostly diagnosed histologically as DLGNTs. Copy-number profiles derived from the methylation arrays revealed unifying characteristics, including loss of chromosomal arm 1p in all cases. Furthermore, this molecular DLGNT class can be subdivided into two subgroups [DLGNT methylation class (MC)-1 and DLGNT methylation class (MC)-2], with all DLGNT-MC-2 additionally displaying a gain of chromosomal arm 1q. Co-deletion of 1p/19q, commonly seen in IDH-mutant oligodendroglioma, was frequently observed in DLGNT, especially in DLGNT-MC-1 cases. Both subgroups also had recurrent genetic alterations leading to an aberrant MAPK/ERK pathway, with KIAA1549:BRAF fusion being the most frequent event. Other alterations included fusions of NTRK1/2/3 and TRIM33:RAF1, adding up to an MAPK/ERK pathway activation identified in 80% of cases. In the DLGNT-MC-1 group, age at diagnosis was significantly lower (median 5 vs 14 years, p < 0.01) and clinical course less aggressive (5-year OS 100, vs 43% in DLGNT-MC-2). Our study proposes an additional molecular layer to the current histopathological classification of DLGNT, of particular use for cases without typical morphological or radiological characteristics, such as diffuse growth and radiologic leptomeningeal dissemination. Recurrent 1p deletion and MAPK/ERK pathway activation represent diagnostic biomarkers and therapeutic targets, respectively-laying the foundation for future clinical trials with, e.g., MEK inhibitors that may improve the clinical outcome of patients with DLGNT.

---

Contributing Institute(s):

1. Pediatric Glioma (B360)
2. B062 Pädiatrische Neuroonkologie (B062)
3. KKE Pädiatrische Onkologie (G340)
4. DKTK Heidelberg (L101)
5. KKE Neuropathologie (G380)

Research Program(s):

1. 312 - Functional and structural genomics (POF3-312) (POF3-312)

Appears in the scientific report 2018

---

Database coverage:
; BIOSIS Previews ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---